Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Cord Blood America Licenses Technology to AXM Pharma in China

publication date: Apr 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Cord Blood America, Inc. has signed a deal licensing its umbilical cord blood technology to AXM Pharma, Inc., a China pharma and nutraceutical company. In addition to the license, Cord Blood America will provide consulting and training. In return, it will receive a 10% equity stake in AXM Pharma's stem cell subsidiary and an 8.5% royalty on all cord blood revenues. More details...

Stock Symbols: (OTCBB: CBAI) (OTCPK: AXMP)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...